drugset / Trial / NCT06698198

Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine Candidate in Healthy Adults (19-49 Years)

NCT06698198

Phase 1 Completed 175 enrolled Sanofi Pasteur, a Sanofi Company
RandomizedParallel-groupTriple-blindPrevention

Summary

This was a Phase I, randomized, active-controlled, observer-blinded, multi-center study to assess the safety and the immunogenicity of 4 Pneumococcal Conjugate Vaccines (PCV) candidates in parallel with Prevnar 13, in Healthy Adults (19-49 years) in the United States.

Timeline

Start
2018-12-03
Primary completion
2019-09-30
Completion
2019-09-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator Prevnar 13 Vaccine Intramuscular
Subject SP0202-I Unknown Intramuscular
Subject SP0202-II Unknown Intramuscular
Subject SP0202-III Unknown Intramuscular
Subject SP0202-IV Unknown Intramuscular